Chronic Liver Disease Management

Underlying Causes and Treatment

Chronic liver disease has several major causes, including hepatitis B, hepatitis C, alcoholic liver disease, hemochromatosis, and nonalcoholic steatohepatitis (NASH), and treatment should target the specific underlying cause 1, 2
The American Association for the Study of Liver Diseases recommends first-line treatments for hepatitis B, including entecavir, tenofovir, or peginterferon alfa-2a 3, 4
Antiviral therapy can eradicate hepatitis C virus in approximately 50% of patients 1
Complete abstinence is usually effective in reversing disease progression in alcoholic liver disease 1
Phlebotomy is effective in preventing progression in hemochromatosis 1
Weight loss and management of metabolic syndrome components are recommended for NASH 1

For hepatitis B patients with elevated ALT and HBV DNA ≥2000 IU/mL, antiviral therapy is recommended by the American Association for the Study of Liver Diseases 5, 3
The European Association for the Study of the Liver recommends liver biopsy or transient elastography to assess histological disease before initiating treatment in patients with normal ALT but elevated HBV DNA 3
Peginterferon has a finite duration of 48-52 weeks, while nucleos(t)ide analogues often require long-term or indefinite therapy 3, 6, 7

All patients with cirrhosis and detectable HBV DNA should receive treatment regardless of ALT levels, according to the American Association for the Study of Liver Diseases 4
First-line options for compensated cirrhosis include entecavir, tenofovir, or peginterferon alfa-2a 8, 4
Lamivudine should be avoided due to high risk of resistance 8, 4
Therapy should be long-term, typically lifelong, even after HBeAg seroconversion 8, 4

All patients with decompensated cirrhosis should receive treatment regardless of HBV DNA level, as recommended by the American Association for the Study of Liver Diseases 8
Preferred options include entecavir, tenofovir monotherapy, or combination therapy with tenofovir plus lamivudine 4, 8
Peginterferon is contraindicated due to risk of further decompensation 8, 4
Renal function should be monitored closely, especially with tenofovir 7

HIV-HBV coinfection is associated with higher HBV DNA levels, more rapid progression to cirrhosis, and 14-fold higher liver-related mortality, and treatment should include agents active against both viruses 8

HBV DNA and ALT levels should be monitored every 3-6 months during therapy, as recommended by the American Association for the Study of Liver Diseases 7
Patients on nucleos(t)ide analogues should be monitored for virologic breakthrough and renal function, especially those on tenofovir or with risk factors for renal impairment 7
Lifelong HCC surveillance is required for cirrhotic patients, even after viral clearance 7

HBV vaccination at birth has shown decreased rates of HCC in endemic regions, according to the Centers for Disease Control and Prevention 1
Early treatment of underlying liver diseases before progression to cirrhosis is the most effective approach for preventing HCC and liver-related mortality, as recommended by the American Association for the Study of Liver Diseases 1
Antiviral therapy in patients with cirrhosis due to hepatitis B has demonstrated decreased rates of HCC 1